Open AccessJournal Article
Novel strategies in the treatment of relapsed/refractory multiple myeloma. From the Multiple Myeloma Research Foundation.
TLDR
An engaging, interactive series of case studies in multiple myeloma, which is available online at www.multiplemyeloma.org and will be published on a regular basis in ONCOLOGY.Abstract:
Trealment regimens for multiple myeloma are evolving because of new advances in both pharmacotherapy and transplantation strategies. The Multiple Myeloma Research Foundation (MMRF) has gathered the top thought leaders in myeloma research to prepare an engaging, interactive series of case studies in multiple myeloma, which are available online at www.multiplemyeloma.org and will be published on a regular basis in ONCOLOGY. For more information about the interactive series, see the MMRF ad on page 1142.read more
Citations
More filters
Journal ArticleDOI
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
Aaron P. Rapoport,Edward A. Stadtmauer,Gwendolyn Binder-Scholl,Olga Goloubeva,Dan T. Vogl,Simon F. Lacey,Ashraf Badros,Alfred L. Garfall,Brendan M. Weiss,Jeffrey Finklestein,Irina Kulikovskaya,Sanjoy K. Sinha,Shari Kronsberg,Minnal Gupta,Sarah Bond,Luca Melchiori,Joanna E. Brewer,Alan D. Bennett,Andrew B. Gerry,Nicholas J. Pumphrey,Daniel Williams,Helen K. Tayton-Martin,Lilliam Ribeiro,Tom Holdich,Saul Yanovich,Nancy M. Hardy,Jean A. Yared,Naseem Kerr,Sunita Philip,Sandra Westphal,Don L. Siegel,Bruce L. Levine,Bent K. Jakobsen,Michael Kalos,Carl H. June +34 more
TL;DR: NY-ESO-1–LAGE-1 TCR–engineered T cells were safe, trafficked to marrow and showed extended persistence that correlated with clinical activity against antigen-positive myeloma, according to the expected mechanism of action of the transferred T cells.
Journal ArticleDOI
Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies.
TL;DR: The hypothesis of the efficacy of a dual approach based on targeting pro-angiogenic pathways and other druggable targets such as mutated oncogenes or the immune system is sustained.
Journal ArticleDOI
Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity
TL;DR: The coculture models of patient pDCs, T cells, or NK cells with autologous MM cells can both delineate mechanisms of immunosuppression and validate targeted novel therapies to restore anti-MM immunity and suggest that RA190 triggers activation of MM patient p DCs.